Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript

Feb 09, 2022 / 05:00PM GMT
Release Date Price: R$42.23 (+0.68%)
Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals

Okay. Great. Thanks, everybody, for joining us. Good afternoon, and welcome to Guggenheim's Fourth Annual Oncology Conference and today's fireside chat discussion with Eli Lilly. I'm Seamus Fernandez, Guggenheim's global biopharma analyst.

I'm joined by Jake Van Naarden, President of Lilly Oncology; and Dr. David Hyman, Chief Medical Officer of Lilly Oncology.

Jake, David, thanks so much for joining us here today.

Questions & Answers

Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals

So I'm going to jump right in with a question for Jake. Jake, coming from what we all assume is a very fast-moving biotech in Loxo Oncology, you've been on the Lilly platform for several years now. I think many people have this feeling that pharma is a slow-moving kind of plotting organizations that just have a lot of capital to deploy. What's been your experience at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot